Patents Issued in July 21, 2020
  • Transmucosal administration system for a pharmaceutical drug
    Patent number: 10716762
    Abstract: The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: July 21, 2020
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Markus Krumme, Keith Jensen, Judith Dubach-Powell, Rudolf Hausmann
  • Transdermal patch containing ropinirole
    Patent number: 10716763
    Abstract: The present invention provides a patch comprising a backing and an adhesive agent layer laminated on the backing, wherein the adhesive agent layer comprises ropinirole or a pharmaceutically acceptable salt thereof, an organic amine or an acid addition salt thereof, and an adhesive agent.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 21, 2020
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Naoyuki Uchida, Yasunari Michinaka
  • Transdermal drug delivery method and system
    Patent number: 10716764
    Abstract: The invention concerns a transdermal delivery system for controlled dispensing of an active substance to and through a porous surface. A certain amount of fluid comprising at least one active substance and at least one solvent is dispensed into an administration reservoir. In the administration reservoir the at least one solvent is separated from the administration reservoir by a solvent recovery means such that the active substance achieves a certain level on an interface device which is permeable for the one active substance. Thereby the active substance is absorbable via diffusion from the interface device by a porous surface to be treated.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: July 21, 2020
    Assignee: Morningside Venture Investments Limited
    Inventors: Werner Zumbrunn, Georgios Imanidis, Guy DiPierro, Hans Werner Van De Venn
  • Delivery of functional compounds
    Patent number: 10716765
    Abstract: Functional ingredients including an esterified component and microencapsulated in an enteric matrix to increase the microencapsulation efficiency and reduce undesired organoleptic properties of the microencapsulated material while providing a desired release rate and ester hydrolysis rate, the process including forming an emulsion in water and titrating the emulsion with a precipitating agent to produce a particulate precipitate.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: July 21, 2020
    Assignee: Intercontinental Great Brands LLC
    Inventors: Anilkumar Ganapati Gaonkar, Les Lawrence, Ahmad Akashe, Amado R. Lopez, Ronald L. Meibach, Dana Sebesta, Yan Wang, James D. White, Leslie G. West
  • Topical regional neuro-affective therapy with cannabinoids
    Patent number: 10716766
    Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a cannabinoid drug(s) to the back of the neck of a human patient to provide regional neuro-affective therapy is disclosed. In certain preferred embodiments, the cannabinoid drug(s) are not psychoactive or substantially not psychoactive. In certain embodiments, the cannabinoid drug(s) are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream. In certain preferred embodiments, the cannabinoid drug(s) comprises cannabidiol.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: July 21, 2020
    Assignee: AfGin Pharma, LLC
    Inventor: Ronald Aung-Din
  • Composition for eye health
    Patent number: 10716767
    Abstract: The nutrient mixture made up of vitamin, carotenoid, micronutrient, essential trace element, and plant extract was much more effective in proactively protecting the corneal cells (human) and retinal pigment endothelial cells (rat) against damaging effects of H2O2 and glycosylated proteins (AGE-BSA) compared to its individual components. A mixture is made up of vitamin A, vitamin C, vitamin E, Lycopene, lutein, marigold flower extract, a saffron extract, pine bark extract, grape seed extract, bilberry extract, lipoic acid, L-Arginine and zinc.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: July 21, 2020
    Inventors: Aleksandra Niedzwiecki, Matthias W Rath, Anna Goc, Waldemar Sumera
  • Method for treating abnormal B-amyloid aggregation mediated diseases
    Patent number: 10716768
    Abstract: The present invention provides a use of a compound to prepare a pharmaceutical composition for treating abnormal ?-amyloid aggregation mediated diseases. The compound is represented by the following formula (I): wherein A, B, R1, R2, R3, R4, R5 and R6 are defined in the specification.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: July 21, 2020
    Assignee: NATIONAL TAIWAN NORMAL UNIVERSITY
    Inventors: Guey-Jen Lee-Chen, Wenwei Lin
  • Method for preventing or treating viral infection and tumor
    Patent number: 10716769
    Abstract: A method for preventing and treating viral infection and tumor using a drug composition having a benzophenone compound and analogues thereof having a symmetrical core structure and having same or different number of hydroxyl substitutions in benzene rings. The drug preparation for preventing and treating HIV, herpes virus and papillomavirus infection and the diseases induced thereby, wherein such viral infections include AIDS, genital warts, flat warts, common warts, herpes simplex, herpes zoster, vaginitis, cervicitis, cervical erosion and senile dementia, as well as cervical cancer, lung cancer, gastric cancer and colon cancer induced thereby. Preparation of hydroxy-substituted benzophenones and analogues thereof together with various compatible excipients into different medicaments or personal disinfected sanitary articles.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: July 21, 2020
    Assignee: GUANGZHOU JTREAT BIOSCI. LTD.
    Inventors: Weihua Qin, Guangyu Jiang
  • Nicotinic receptor non-competitive antagonists
    Patent number: 10716770
    Abstract: The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for use, and their pharmaceutical compositions.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: July 21, 2020
    Assignee: Catalyst Biosciences, Inc.
    Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Ronald Joseph Heemstra, Jason Speake, Daniel Yohannes, Matt S. Melvin, Yunde Xiao
  • Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient
    Patent number: 10716771
    Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: July 21, 2020
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC CORPORATION FOUNDATION
    Inventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
  • Double targeted constructs to affect tumor kill
    Patent number: 10716772
    Abstract: The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: July 21, 2020
    Assignee: Cornell University
    Inventors: John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
  • Compositions comprising 15-HEPE and methods of treating or preventing cancer and neurologic disease
    Patent number: 10716773
    Abstract: The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing cancer and neurological diseases in a subject in need thereof.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: July 21, 2020
    Assignee: Afimmune Limited
    Inventors: John Climax, David Coughlan
  • Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
    Patent number: 10716774
    Abstract: Isotretinoin compositions having improved bioavailability are disclosed. The compositions are oral formulations containing isotretinoin, a lipid excipient and a cosolvent, wherein the ratio of isotretinoin to the lipid excipient is from about 1:1.2 to about 1:1.6. The compositions can be in the form of a pharmaceutically acceptable oral dosage form such as a capsule or compressed tablet wherein the isotretinoin is adsorbed onto blended particles of a cellulosic polymer and silicon dioxide in combination with a lipid excipient such as soy phosphatidylcholine and a cosolvent such as propylene glycol. Methods of preparing the compositions and methods of treatment using the compositions are also disclosed.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 21, 2020
    Assignee: YALE PHARMACEUTICALS LLC
    Inventor: Basavaraj Siddalingappa
  • Composition for preventing the occurrence of cardiovascular event in multiple risk patient
    Patent number: 10716775
    Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: July 21, 2020
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
    Patent number: 10716776
    Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject.
    Type: Grant
    Filed: July 21, 2019
    Date of Patent: July 21, 2020
    Assignee: SCF PHARMA INC.
    Inventor: Samuel C. Fortin
  • Antitumoral use of cabazitaxel
    Patent number: 10716777
    Abstract: The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: July 21, 2020
    Assignee: SANOFI MATURE IP
    Inventor: Sunil Gupta
  • Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals
    Patent number: 10716778
    Abstract: The present disclosure relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular, in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, Alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise. The composition also has a use in veterinary applications for increasing the growth and immunity in animals.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: July 21, 2020
    Assignee: Veijlen
    Inventors: Hubert Jean-Marie Francois Gillessen, Christian Rebiere
  • Methods and compositions for treating foot or hand pain
    Patent number: 10716779
    Abstract: The present disclosure provides novel formulations for treating foot or hand pain by topically administering a sympathomimetic drug, particularly oxymetazoline, to the skin of the foot or hand.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: July 21, 2020
    Inventor: Jennifer L. Sanders
  • Topical retinoid compositions
    Patent number: 10716781
    Abstract: The present application relates to topical compositions. In particular, the present application relates to a topical composition comprising retinoid as active agent, and pharmaceutically acceptable excipient(s), and a process of preparing such compositions. Further, the present application relates to method of using topical compositions for the treatment of skin disorders such as acne, rosacea, psoriasis etc.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 21, 2020
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Sateesh Kandavilli, Franklin Okumu, Manish M. Bankar, Sujit Kumar Dolai
  • LPT-723 and immune checkpoint inhibitor combinations and methods of treatment
    Patent number: 10716782
    Abstract: The present invention provides, inter alia, a composition containing a compound of formula (I): or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: July 21, 2020
    Assignee: BIOMED VALLEY DISCOVERIES, INC.
    Inventors: Saurabh Saha, Linping Zhang, Xiaoyan Michelle Zhang
  • Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom
    Patent number: 10716783
    Abstract: Methods for treating a patient suffering from neural cell injury, the method comprising administering to the patient an effective amount of a HIF prolyl-4-hydroxylase inhibiting compound having the following general formula (1) wherein R1 is a cyclic group containing at least three and up to seven carbon atoms and optionally containing one or more heteroatoms selected from O, N, and S, and optionally attached to the shown carbon atom by a linking group; R2 is independently selected from said cyclic groups of R1 and acyclic hydrocarbon groups R5 containing up to twenty carbon atoms; R3 is selected from hydrogen atom and hydrocarbon groups containing up to six carbon atoms; R6 and R7 are independently selected from hydrogen atom, hydrocarbon groups containing up to three carbon atoms, halogen atom, and polar groups, as well as methylene-linked versions thereof; and t is 0 or 1.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: July 21, 2020
    Assignee: CORNELL UNIVERSITY
    Inventors: Rajiv R. Ratan, Saravanan S. Karuppagounder
  • Pain medicine combination and uses thereof
    Patent number: 10716784
    Abstract: This application describes compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: July 21, 2020
    Assignee: MINDLAB LLC
    Inventors: Lawrence R. James, Laura A. James
  • Methods for treating antipsychotic-induced weight gain
    Patent number: 10716785
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: July 21, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Transmucosal and subcutaneous compositions
    Patent number: 10716786
    Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: July 21, 2020
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Wei Yao, Robert Davis
  • Combinations
    Patent number: 10716787
    Abstract: The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof; and a second compound which is a cMet inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: July 21, 2020
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Eleonora Jovcheva, Timothy Pietro Suren Perera
  • Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10716788
    Abstract: The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: July 21, 2020
    Assignee: Merck Patent GmbH
    Inventor: Tammy Dellovade
  • Co-crystals and pharmaceutical compositions comprising the same
    Patent number: 10716789
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: July 21, 2020
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael P. Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Method for treating cancer by combined use
    Patent number: 10716790
    Abstract: It is intended to provide a medicament and a method for treating cancer comprising a compound having MDM2 inhibiting activity and a compound having FLT3 inhibiting activity in combination. The present invention provides a medicament comprising (3?R,4?S,5?R)—N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6?-chloro-4?-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2?-oxo-1?,2?-dihydrodispiro[cyclohexane-1,2?-pyrrolidine-3?,3?-indole]-5?-carboxamide or a pharmaceutically acceptable salt thereof and N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof in combination, and a treatment method using these compounds or salts in combination.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 21, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Takahiko Seki
  • Inhibitors of peptidyl arginine deiminase (PAD) enzymes and uses thereof
    Patent number: 10716791
    Abstract: The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or associated with the hypercitrullination of proteins by peptidyl arginine deiminase (PAD) enzymes.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: July 21, 2020
    Assignee: University Health Network
    Inventors: Lakshmi P. Kotra, Ewa Wasilewski
  • Neuroquiescence—a treatment for neurological and nervous system bioelectrical dysregulation associated with seizures of epilepsy
    Patent number: 10716792
    Abstract: The present inventive concept describes a method for treating the neurovascular disruption underlying Epileptic Seizures and other traits of Epilepsy and Infantile Spasms by improving the neurophysiological environment and then enabling by sustained sedation a biomechanism of glial cells for neuronal repairs.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: July 21, 2020
    Inventors: Gary Aaron Howard, Debora Zucco Sassi Yonezawa Siviglia
  • Treprostinil administration by inhalation
    Patent number: 10716793
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: July 21, 2020
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • High-strength testosterone undecanoate compositions
    Patent number: 10716794
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: July 21, 2020
    Assignee: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
  • Steroid analogues for neuroprotection
    Patent number: 10716795
    Abstract: Provided are steroid analogues functionalized with polar substituents at the C3 and/or C20 positions of the steroid ring system that exhibit improved water solubility. Also provided are pharmaceutical compositions comprising the steroid analogues and methods using the novel steroid analogues for the treatment and prevention of neurodegeneration in a patient following injury to the central nervous system.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: July 21, 2020
    Assignee: Emory University
    Inventors: Christopher MacNevin, Donald G. Stein, Dennis C. Liotta, Iqbal Sayeed, David B. Guthrie, Mark A. Lockwood, Michael G. Natchus
  • Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
    Patent number: 10716796
    Abstract: The present invention refers to a new enzymatic process for obtaining 17?-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17?,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17?-propionate and 9,11-dehydro-cortexolone 17?-butanoate.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: July 21, 2020
    Assignee: CASSIOPEA S.P.A.
    Inventors: Mauro Ajani, Luigi Moro
  • Steroid alkaloids and compositions and kits thereof
    Patent number: 10716797
    Abstract: The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): There are provided compositions and kits using such compounds and inhibitors.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: July 21, 2020
    Assignee: SOCPRA SCIENCES ET GÉNIE S.E.C.
    Inventors: Éric Marsault, François Malouin, Félix Chagnon, Isabelle Guay, Simon Boulanger
  • Compositions and methods for tranquilizing heart muscle
    Patent number: 10716798
    Abstract: A pharmaceutical composition for tranquilizing cardiomyocytes present in heart muscle in a subject diagnosed with a cardiac overload disease comprises a therapeutically effective amount of a Vitamin D5 compound and a pharmaceutically acceptable excipient. A method for treating or preventing heart failure in a subject diagnosed as having heart failure or being at risk for heart failure, comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a Vitamin D5 compound and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: July 21, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventor: Robert U. Simpson
  • Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
    Patent number: 10716799
    Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analogue and a corticosteroid, and its use in the treatment of dermal diseases and conditions.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 21, 2020
    Assignee: LEO Pharma A/S
    Inventors: Marianne Lind, Gritt Rasmussen, Mette Rydahl Sonne, Jens Hansen, Karsten Petersson
  • Conjugates of a phospholipid and a drug for the treatment of inflammatory bowel disease
    Patent number: 10716800
    Abstract: Conjugates of drugs suitable for use in the treatment of inflammatory bowel disease and phospholipids, and their use in the treatment of inflammatory bowel disease, are disclosed. The disclosed conjugates serve as targeted prodrugs which are suitable for oral administration, and which are capable of releasing the drug selectively at the diseased tissue upon activation by PLA2.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: July 21, 2020
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventor: Arik Dahan
  • Silanol based therapeutic payloads
    Patent number: 10716801
    Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: July 21, 2020
    Assignee: BlinkBio, Inc.
    Inventors: Hanh Nho Nguyen, Leslie Odame Ofori, Jutta Wanner, Douglas S. Werner
  • Compounds to modulate intestinal absorption of nutrients
    Patent number: 10716802
    Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 21, 2020
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Jeffrey M. Karp, Yuhan Lee, Ali Tavakkoli, Tarawatie E. Deelman
  • Methods for treatment or prevention of damage resulting from radiation, trauma or shock
    Patent number: 10716803
    Abstract: Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: July 21, 2020
    Assignee: SYNEDGEN, INC.
    Inventors: Shenda M. Baker, William P. Wiesmann
  • Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease
    Patent number: 10716804
    Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: July 21, 2020
    Assignee: SEIKAGAKU CORPORATION
    Inventor: Sho Funayama
  • Formulation for release of nitric oxide
    Patent number: 10716805
    Abstract: A composition for releasing nitric oxide which provides a rapid release of nitrogen monoxide, and also allows formation of S-nitrosothiol compounds which provide a slower extended release of nitrogen monoxide. A composition kit includes two components that are mixed together to initiate nitric oxide release. The kit includes: a liquid phase comprising a solvent and at least one reducing agent; and a solid phase comprising a nitrate and/or nitrite salt, copper ions and at least one thiol. A method of treating sexual dysfunction involves topically applying the composition to an area of the subject to be treated.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: July 21, 2020
    Assignee: Glanotech Limited
    Inventors: Gioacchino Di Leo, Luciano Caglioti, Alberto Boffi, Luciana Mosca, Robert Giovanni Nisticò
  • Solution of carbon monoxide for the treatment of disease, including sickle cell disease
    Patent number: 10716806
    Abstract: The invention provides compositions and methods for delivering carbon monoxide (CO) to subjects suffering from inflammatory, cardiovascular, Sickle Cell, and other disease. The compositions are liquids, including Newtonian and non-Newtonian liquids, such as pastes, gels, foams, emulsions, and other non-gaseous compositions, in which CO is dissolved at an amount that, when administered to a patient, provides a therapeutically or prophylactically effective amount of CO to the patient. The compositions can be provided in many forms, including in bottles or cans.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: July 21, 2020
    Assignee: CHILDREN'S HOSPITAL LOS ANGELES
    Inventors: Edward D. Gomperts, Henry J. Forman
  • Method of treating relapsing-remitting multiple sclerosis using arsenic trioxide
    Patent number: 10716807
    Abstract: The present invention relates to a method for preventing or treating multiple sclerosis, particularly relapsing-remitting multiple sclerosis using arsenic trioxide.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: July 21, 2020
    Assignee: MEDSENIC
    Inventor: François Rieger
  • Methods and compositions to modulate hair growth
    Patent number: 10716808
    Abstract: Embodiments of the methods and compositions provided herein relate to inducing hair growth in a subject. Some embodiments include screening for agents to modulate hair growth.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: July 21, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventor: Alexey V. Terskikh
  • Methods of producing enriched populations of tumor reactive T cells from peripheral blood
    Patent number: 10716809
    Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+ T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: July 21, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes
    Patent number: 10716810
    Abstract: Described are compositions of matter, protocols, and treatment means for induction of immune mediated killing in dogs suffering from cancer. The invention provides means of extracting peripheral blood from a canine patient, expanding immunocytes capable of killing cancer cells in vitro, and re-administering said immunocytes into a patient in need of therapy. In one embodiment, immunocytes expanded are T cells possessing tumor cytotoxic activity induced by stimulation of NKG2D.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: July 21, 2020
    Assignee: Zander Therapeutics, Inc.
    Inventors: Thomas Ichim, David Koos
  • Compositions and methods related to multimodal therapeutic cancer indications
    Patent number: 10716811
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: July 21, 2020
    Assignee: Rubius Therapeutics Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Multilayered blood product
    Patent number: 10716812
    Abstract: A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: July 21, 2020
    Assignee: Reapplix APS
    Inventors: Rasmus Lundquist, Niels Erik Holm